uracil and incretins

uracil has been researched along with incretins in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (8.33)	29.6817
2010's	11 (91.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Argyrakopoulou, G; Doupis, J	1
Cefalu, WT	1
Gerich, J	1
Cersosimo, E; DeFronzo, RA; Triplitt, C	1
Deshpande, SS; Ghatak, SB; Panchal, SJ; Patel, DS; Shanker, N; Srivstava, A	1
Boudes, P; Viereck, C	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Ishikawa, M; Yamada, Y	1
Burciu, C; Koska, J; Reaven, P; Sands, M	1
Baker, WL; White, WB	1
Jermendy, G	1
Mannucci, E; Monami, M	1

Reviews

10 review(s) available for uracil and incretins

Article	Year
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil	2009
The physiologic role of incretin hormones: clinical applications. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vascular health and risk management, 2010, Sep-07, Volume: 6 Topics: Animals; Cardiovascular System; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipid Metabolism; Liver; Mice; Pioglitazone; Piperidines; Rats; Thiazolidinediones; Uracil	2010
Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Current diabetes reviews, 2010, Volume: 6, Issue:6 Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Humans; Incretins; Insulin-Secreting Cells; Piperidines; Structure-Activity Relationship; Uracil	2010
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diabetes & vascular disease research, 2015, Volume: 12, Issue:3 Topics: Adamantane; Animals; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incretins; Piperidines; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Uracil	2015
Cardiovascular Effects of Incretin-Based Therapies. Annual review of medicine, 2016, Volume: 67 Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Piperidines; Sitagliptin Phosphate; Uracil	2016
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials]. Orvosi hetilap, 2016, Apr-17, Volume: 157, Issue:16 Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Incretins; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Uracil	2016
Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in therapy, 2017, Volume: 34, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Meta-Analysis as Topic; Peptides; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil	2017

Other Studies

2 other study(ies) available for uracil and incretins

Article	Year
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin	2011
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012

Article

Year

An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

Contemporary clinical trials, 2011, Volume: 32, Issue:3

Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin

2011

[Therapeutic use and adverse events of incretin-related drugs].

Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3

Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin

2012